| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 19 Feb 2025 | 14 Feb 2025 |
| VISTA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/02/2025 inter alia to consider and approve 1. The proposal of raising of funds by way of issue of equity or convertible warrants on preferential basis subject to the receipt of necessary approvals/permissions. 2. To approve the Notice of the Extraordinary General Meeting for the approval of raising of funds. 3. Any other business with the permission of the Chair. Outcome of Board meeting under regulation 30 of SEBI (Listing obligation and disclosure requirement Regulation), 2015 (As Per BSE Announcement Dated on: 19/02/2025) | ||
| Board Meeting | 12 Feb 2025 | 3 Feb 2025 |
| VISTA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 inter alia to consider and approve 1. Un-Audited financial results for the quarter ended 31.12.2024. 2. Limited Review Report for quarter ended 31.12.2024. 3. Any other business with the permission of the Chair. | ||
| Board Meeting | 13 Nov 2024 | 7 Nov 2024 |
| VISTA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve 1. Un Audited financial results for the quarter ended 30.09.2024. 2. Limited Review Report for quarter ended 30.09.2024 3. Any other business with the permission of the Chair. outcome of the Board Meeting under Regulation 30 read with 33 (3) of SEBI (LODR) Regulation 2015 (As per BSE Announcement Dated on 13/11/2024) | ||
| Board Meeting | 13 Aug 2024 | 3 Aug 2024 |
| VISTA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve 1. Un Audited financial results for the quarter ended 30.06.2024. 2. Limited Review Report for quarter ended 30.06.2024 3. Any other business with the permission of the Chair. Financial results fro the quarter ended 30.06.2024 (As Per BSE Announcement Dated on: 13/08/2024) | ||
| Board Meeting | 12 Jun 2024 | 14 Jun 2024 |
| Circular Resolution | ||
| Board Meeting | 28 May 2024 | 21 May 2024 |
| VISTA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve 1. Audited financial results for the quarter and year ended 31.03.2024. 2. Audit Report for quarter and year ended 31.03.2024. 3. Conversion of warrants into equity shares of the Company to the Non-Promoters subject to the depositing the balance outstanding amount for conversion of warrants into the equity shares of the Company. 4. Any other business with the permission of the Chair. Board Meeting outcome (As per BSE Announcement Dated on 28/05/2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
